Literature DB >> 3049065

The relevance of plasminogen activators to neoplastic growth. A review of recent literature.

G Markus1.   

Abstract

The topics reviewed in this article include transcriptional regulation of plasminogen activators, their relevance to differentiation, tumor progression, and to the metastatic spread of cancer. Recent information on the nature of cellular plasminogen activator receptors is also discussed. Particular attention is paid to the increasing number of observations indicating that several of the inducers of plasminogen activator synthesis utilize distinct regulatory pathways.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3049065     DOI: 10.1159/000469158

Source DB:  PubMed          Journal:  Enzyme        ISSN: 0013-9432


  18 in total

1.  Blueberry phytochemicals inhibit growth and metastatic potential of MDA-MB-231 breast cancer cells through modulation of the phosphatidylinositol 3-kinase pathway.

Authors:  Lynn S Adams; Sheryl Phung; Natalie Yee; Navindra P Seeram; Liya Li; Shiuan Chen
Journal:  Cancer Res       Date:  2010-04-13       Impact factor: 12.701

2.  Urokinase-type plasminogen activator receptor in gastric cancer: tissue expression and prognostic role.

Authors:  M Plebani; L Herszènyi; P Carraro; M De Paoli; G Roveroni; R Cardin; Z Tulassay; R Naccarato; F Farinati
Journal:  Clin Exp Metastasis       Date:  1997-07       Impact factor: 5.150

3.  Gastric mucosal plasminogen activators in Helicobacter pylori infection.

Authors:  J M Götz; Y Vergouwe; H W Verspaget; I Biemond; C F Sier; C B Lamers; R A Veenendaal
Journal:  Dig Dis Sci       Date:  1996-08       Impact factor: 3.199

4.  Expression of plasminogen activator inhibitor type 1 by human prostate carcinoma cells inhibits primary tumor growth, tumor-associated angiogenesis, and metastasis to lung and liver in an athymic mouse model.

Authors:  G A Soff; J Sanderowitz; S Gately; E Verrusio; I Weiss; S Brem; H C Kwaan
Journal:  J Clin Invest       Date:  1995-12       Impact factor: 14.808

Review 5.  Plasmin activation system in restenosis: role in pathogenesis and clinical prediction?

Authors:  G Christ; K Kostner; M Zehetgruber; B R Binder; D Gulba; K Huber
Journal:  J Thromb Thrombolysis       Date:  1999-06       Impact factor: 2.300

6.  Effect of retinoic acid on human neuroblastoma: correlation between morphological differentiation and changes in plasminogen activator and inhibitor activity.

Authors:  L A Benjamin; R C McGarry; D A Hart
Journal:  Cancer Chemother Pharmacol       Date:  1989       Impact factor: 3.333

7.  Urokinase (uPA) and its inhibitor PAI-1 are strong and independent prognostic factors in node-negative breast cancer.

Authors:  F Jänicke; M Schmitt; L Pache; K Ulm; N Harbeck; H Höfler; H Graeff
Journal:  Breast Cancer Res Treat       Date:  1993       Impact factor: 4.872

8.  Plasminogen activators in normal tissue and carcinomas of the human oesophagus and stomach.

Authors:  C F Sier; H W Verspaget; G Griffioen; S Ganesh; H J Vloedgraven; C B Lamers
Journal:  Gut       Date:  1993-01       Impact factor: 23.059

Review 9.  The plasminogen-plasmin system in malignancy.

Authors:  H C Kwaan
Journal:  Cancer Metastasis Rev       Date:  1992-11       Impact factor: 9.264

10.  Effects of suramin on metastatic ability, proliferation, and production of urokinase-type plasminogen activator and plasminogen activator inhibitor type 2 in human renal cell carcinoma cell line SN12C-PM6.

Authors:  K Marutsuka; Y Hasui; Y Asada; S Naito; Y Osada; A Sumiyoshi
Journal:  Clin Exp Metastasis       Date:  1995-03       Impact factor: 5.150

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.